サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：BCMA標的療法市場：タイプ別、がん別、エンドユーザー別、国別、地域別：産業分析、市場規模、市場シェア、2024-2032年予測
市場調査レポート
商品コード
1419021

BCMA標的療法市場：タイプ別、がん別、エンドユーザー別、国別、地域別：産業分析、市場規模、市場シェア、2024-2032年予測

Bcma Targeted Therapies Market, By Type, By Cancer, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 299 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
BCMA標的療法市場：タイプ別、がん別、エンドユーザー別、国別、地域別：産業分析、市場規模、市場シェア、2024-2032年予測
出版日: 2024年01月17日
発行: AnalystView Market Insights
ページ情報: 英文 299 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

BCMA標的療法市場規模は2023年に90億1,000万米ドルとなり、2024年から2032年にかけてCAGR 20.5％で拡大する見込みです。

BCMA標的療法市場- 市場力学

多発性骨髄腫の再発症例数の増加が、B細胞成熟抗原（BCMA）標的療法市場の成長を促進すると予想される

標的治療などのBCMA標的療法は、BCMAを発現するがん細胞に特異的に焦点を当てることで、より正確な方法を提供します。このアプローチは、より効果的で害の少ない治療をもたらす可能性があり、それによってアンメット・メディカルな要求に応えることができます。米国臨床腫瘍学会によると、2023年には米国で推定35,730人（男性19,860人、女性15,870人）の成人が多発性骨髄腫と診断されます。世界では、2020年に推定176,404人が多発性骨髄腫と診断されました。さらに、多発性骨髄腫の分子的・遺伝的基盤の解明が進むことで、新たな治療標的が同定され、より強力なBCMA標的療法が開発される可能性があります。しかし、これらの治療法のコストが高いことが市場成長の妨げになる可能性があることに留意することが重要です。

BCMA標的療法市場-セグメンテーション分析：

BCMA標的療法の世界市場は、タイプ、がん、エンドユーザー、地域に基づいて区分されます。

市場はタイプによって3つのカテゴリーに分けられる：市場は、二重特異性抗体、抗体薬物複合体、キメラ抗原受容体T細胞の3つのタイプに分類されます。多発性骨髄腫細胞は形質細胞を侵すがんの一種で、表面にBCMAと呼ばれるタンパク質を発現しています。CAR-T細胞療法は、がん細胞を識別して攻撃するキメラ抗原受容体（CAR）を発現するように患者自身のT細胞を改変する免疫療法アプローチです。

市場はがんの種類によって3つのグループに区分される：肝臓がん、呼吸器がん、脳腫瘍、その他。B細胞成熟抗原（BCMA）標的療法は、主に形質細胞に影響を与えるがんの一種である多発性骨髄腫の治療に用いられてきました。BCMAは多発性骨髄腫細胞の表面に存在するため、治療介入の格好の標的となります。

市場はエンドユーザー別に病院とがん研究所の2つに分類されます。同市場は、主に病院セクターが支配しています。患者のケアとサポートサービスを向上させるため、病院はBCMA標的治療の潜在的な副作用の管理と、治療を受けている患者への包括的なケアの提供に注力しなければならない可能性があります。病院は、がん治療の実施に関する規制要件を遵守し、医療当局が定めた安全性と有効性の基準に沿ったプロトコールを確実に実施することが極めて重要です。

BCMA標的療法市場-地理的洞察

地理的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカなど様々な地域に広がっています。これらの地域は、事業活動を行っている国に基づいてさらに区分されます。多発性骨髄腫に対する革新的な治療法の研究開発への投資が増加していることを主因として、市場の成長は北米が独占すると予想されます。米国は臨床研究の主要拠点として、多発性骨髄腫を含む様々な疾患に対する数多くの臨床試験が実施されています。著名な研究機関、学術医療センター、バイオテクノロジー企業が存在することで、臨床試験を実施するための強力なインフラが構築され、新たな治療法の開発が促進されています。国民医療費によると、米国（U.S.）の医療・健康研究開発（R&D）投資は大幅に増加し、2020年には2019年から11.1％増の2,451億米ドルに達しました。官民のR&Dエコシステムの成長率は2020年に変化を見せたが、これはCOVID-19パンデミックへの対応とその影響によるものと思われます。

BCMA標的療法市場-競合情勢：

BCMA標的療法市場はダイナミックな競合情勢を特徴としており、数多くの製薬企業やバイオテクノロジー企業がこれらの治療薬の開発に積極的に取り組んでいます。これらの治療薬は、多発性骨髄腫、特に再発または他の治療選択肢に抵抗性を示した患者に対する臨床的有効性を実証しています。現在、多くの企業が前臨床段階と臨床段階の両方において、BCMAを標的とした治療法の開発に携わっており、BCMA単体の治療法として、または他の薬剤との併用療法として開発されています。一例として、2023年1月31日、細胞・遺伝子治療を専門とする臨床段階の企業であるポセイダ・セラピューティクス社は、2023年2月3日付でエリック・オスターターグ医学博士の取締役会長辞任と取締役会からの退任を発表しました。ただし、オスタータグ博士はコンサルタントとして引き続き当社に貢献し、技術的・科学的事項に関して貴重な専門知識を提供します。

目次

第1章 BCMA標的療法市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 Bcma標的療法の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 BCMA標的療法産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 BCMA標的療法市場：COVID-19感染症の影響分析

  • プレCOVID-19の影響分析
  • ポストCOVID-19の影響分析

第6章 BCMA標的療法市場情勢

  • BCMA標的療法市場シェア分析、2023年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 BCMA標的療法市場- タイプ別

  • 概要
    • タイプ別セグメントシェア分析
    • 二重特異性抗体
    • 抗体薬物複合体
    • キメラ抗原受容体T細胞

第8章 BCMA標的療法市場- がん別

  • 概要
    • がん別セグメントシェア分析
    • 肝臓がん
    • 呼吸器がん
    • 脳腫瘍
    • その他

第9章 BCMA標的療法市場- エンドユーザー別

  • 概要
    • エンドユーザー別のセグメントシェア分析
    • 病院
    • がん研究

第10章 BCMA標的療法市場-地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析-BCMA標的療法業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Transposagen Biopharmaceuticals
    • Sutro Biopharma
    • Malin Corporation
    • Eureka Therapeutics
    • firstVentury Equity
    • Five Prime Therapeutics
    • Credit Suisse Securities
    • Dana-Farber Cancer Institute
    • Deerfield Partners
    • Onyx Pharmaceuticals
    • Juno Therapeutics

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Bcma Targeted Therapies Market: Type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Bcma Targeted Therapies Market, by Type 2019-2032 (USD Million)
  • TABLE Bcma Targeted Therapies Market: Cancer Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Cancer
  • TABLE Global Bcma Targeted Therapies Market, by Cancer 2019-2032 (USD Million)
  • TABLE Bcma Targeted Therapies Market: End-User Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by End-User
  • TABLE Global Bcma Targeted Therapies Market, by End-User 2019-2032 (USD Million)
  • TABLE Bcma Targeted Therapies Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Bcma Targeted Therapies Market, by Region 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE North America Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Europe Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Asia Pacific Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Latin America Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by Type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by Cancer, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Bcma Targeted Therapies Market, by End-User, 2019-2032 (USD Million)

List of Figures

  • FIGURE Bcma Targeted Therapies Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2023
  • FIGURE Type segment market share analysis, 2023 & 2032
  • FIGURE Type segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Cancer segment market share analysis, 2023 & 2032
  • FIGURE Cancer segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE End-User segment market share analysis, 2023 & 2032
  • FIGURE End-User segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Regional segment market share analysis, 2023 & 2032
  • FIGURE Regional segment market size forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE North America Bcma Targeted Therapies Market share and leading players, 2023
  • FIGURE Europe Bcma Targeted Therapies Market share and leading players, 2023
  • FIGURE Asia Pacific Bcma Targeted Therapies Market share and leading players, 2023
  • FIGURE Latin America Bcma Targeted Therapies Market share and leading players, 2023
  • FIGURE Middle East and Africa Bcma Targeted Therapies Market share and leading players, 2023
  • FIGURE North America market share analysis by country, 2023
  • FIGURE U.S. Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Canada Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Europe Bcma Targeted Therapies Market share analysis by country, 2023
  • FIGURE Germany Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Spain Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Italy Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE France Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE UK Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Russia Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Netherlands Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Sweden Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Poland Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of the Europe Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Asia Pacific Bcma Targeted Therapies Market share analysis by country, 2023
  • FIGURE India Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE China Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Japan Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE South Korea Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Australia Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Thailand Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Indonesia Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Phillipines Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of APAC Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Latin America Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Latin America Bcma Targeted Therapies Market share analysis by country, 2023
  • FIGURE Brazil Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Mexico Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Argentina Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Colombia Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of LATAM Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Middle East and Africa Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Middle East and Africa Bcma Targeted Therapies Market share analysis by country, 2023
  • FIGURE Saudi Arabia Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE United Arab Emirates Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Israel Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Turkey Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Algeria Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Egypt Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
  • FIGURE Rest of MEA Bcma Targeted Therapies Market size, forecast and trend analysis, 2019 to 2032 (USD Million)
目次
Product Code: ANV2086

REPORT HIGHLIGHT

Bcma Targeted Therapies Market size was valued at USD 9,010 Million in 2023, expanding at a CAGR of 20.5% from 2024 to 2032.

BCMA, or B cell maturation antigen, has emerged as a promising treatment target for multiple myeloma (MM) due to its highly specific expression in malignant plasma cells (PCs). Various BCMA-targeted therapies, such as antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have shown remarkable clinical responses in patients with relapsed and refractory MM. The introduction of novel therapeutics like proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has further enhanced the treatment outcomes for patients with MM. It is estimated that there will be over 275,000 new cases of multiple myeloma worldwide by 2040. Multiple myeloma is a type of blood cancer characterized by the abnormal proliferation of malignant plasma cells, primarily originating in the bone marrow. BCMA, a cell surface antigen predominantly found in multiple myeloma cases, presents a valuable target for therapeutic interventions in this disease.

Bcma Targeted Therapies Market- Market Dynamics

Increasing number of recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market

BCMA-targeted therapies, such as targeted treatments, provide a more precise method by specifically focusing on cancer cells that express BCMA. This approach has the potential to result in treatments that are more effective and less harmful, thereby addressing the unmet medical requirements. According to the American Society of Clinical Oncology, In 2023, an estimated 35,730 adults (19,860 men and 15,870 women) in the United States will be diagnosed with multiple myeloma. Worldwide, an estimated 176,404 people were diagnosed with multiple myeloma in 2020. Additionally, ongoing advancements in comprehending the molecular and genetic foundations of multiple myeloma may lead to the identification of new therapeutic targets and the development of more potent BCMA-targeted therapies. However, it is important to note that the high cost of these therapies may hinder market growth.

Bcma Targeted Therapies Market- Key Insights

  • As per the analysis shared by our research analyst, the global Bcma Targeted Therapies market is estimated to grow annually at a CAGR of around 20.5% over the forecast period (2024-2032)
  • Based on Type segmentation, Chimeric Antigen Receptor T-Cells was predicted to show maximum market share in the year 2023
  • Based on End-User segmentation, Hospitals was the leading type in 2023
  • On the basis of region, North America was the leading revenue generator in 2023

Bcma Targeted Therapies Market- Segmentation Analysis:

The Global Bcma Targeted Therapies Market is segmented on the basis of Type, Cancer, End-User, and Region.

The market is divided into three categories based on Type: Bispecific Antibodies, Antibody Drug Conjugates and Chimeric Antigen Receptor T-Cells.The market is largely dominated by the segment of Chimeric Antigen Receptor T-Cells. Multiple myeloma cells, which are a type of cancer that affects plasma cells, express a protein called BCMA on their surface. CAR-T cell therapy is an immunotherapy approach that involves modifying the patient's own T cells to express a chimeric antigen receptor (CAR) capable of identifying and attacking cancer cells.

The market is segmented into three groups according to the type of cancer: Liver Cancer, Respiratory Cancer, Brain Cancer, and Others. B-Cell Maturation Antigen (BCMA) targeted therapies have mainly been used in the treatment of multiple myeloma, a form of cancer that impacts plasma cells. BCMA is present on the surface of multiple myeloma cells, which makes it a prime target for therapeutic interventions.

The market is divided into two categories based on End-User: Hospitals and Cancer Research Institute. The market is largely controlled by the hospitals sector. In order to improve patient care and support services, hospitals may have to focus on managing the potential side effects of BCMA-targeted therapies and providing comprehensive care for patients receiving treatment. It is crucial for hospitals to comply with regulatory requirements for the administration of cancer treatments, ensuring that protocols are in line with the safety and efficacy standards set by health authorities.

Bcma Targeted Therapies Market- Geographical Insights

Geographically, this market is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increasing investments in research and development of innovative therapies for multiple myeloma. The United States serves as a major center for clinical research, hosting numerous clinical trials for various diseases, including multiple myeloma. The presence of renowned research institutions, academic medical centers, and biotechnology companies contributes to a strong infrastructure for conducting clinical trials, thereby facilitating the development of new therapies. According to the National Health Expenditures, the United States (U.S.) witnessed a significant increase in medical and health research and development (R&D) investment, reaching USD 245.1 billion in 2020, marking an 11.1% rise from 2019. The growth rates in the public-private sector R&D ecosystem underwent changes in 2020, likely influenced by the response to and impact of the COVID-19 pandemic.

Bcma Targeted Therapies Market- Competitive Landscape:

The BCMA-targeted therapies market is characterized by a dynamic competitive landscape, with numerous pharmaceutical and biotechnology companies actively engaged in the development of these treatments. These therapies have demonstrated clinical effectiveness in addressing multiple myeloma, particularly in patients who have relapsed or shown resistance to other treatment options. Many companies are currently involved in both preclinical and clinical stages of developing BCMA-targeted therapies, either as standalone treatments or in combination with other drugs. As an example, on January 31, 2023, Poseida Therapeutics, Inc., a clinical-stage company specializing in cell and gene therapy, announced the resignation of Dr. Eric Ostertag, M.D., Ph.D., as Executive Chairman and his retirement from the Board of Directors, effective February 3, 2023. However, Dr. Ostertag will continue to contribute to the company as a consultant, providing valuable expertise in technical and scientific matters.

Recent Developments:

November 17, 2022, More than 275,000 new cases of multiple myeloma are expected to occur globally by the year 2040. Multiple myeloma is a blood cancer characterized by the proliferation of malignant plasma cells that typically originate in the bone marrow. B-cell maturation antigen (BCMA) is an important cell surface antigen found in nearly all cases of multiple myeloma, but with limited expression on normal tissues other than plasma cells. This makes it a key target for multiple myeloma therapeutics.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BCMA TARGETED THERAPIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Transposagen Biopharmaceuticals
  • Sutro Biopharma
  • Malin Corporation
  • Eureka Therapeutics
  • firstVentury Equity
  • Five Prime Therapeutics
  • Credit Suisse Securities
  • Dana-Farber Cancer Institute
  • Deerfield Partners
  • Onyx Pharmaceuticals
  • Juno Therapeutics

GLOBAL BCMA TARGETED THERAPIES MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Bispecific Antibodies
  • Antibody Drug Conjugates
  • Chimeric Antigen Receptor T-Cells

GLOBAL BCMA TARGETED THERAPIES MARKET, BY CANCER- MARKET ANALYSIS, 2019 - 2032

  • Liver Cancer
  • Respiratory Cancer
  • Brain Cancer
  • Others

GLOBAL BCMA TARGETED THERAPIES MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Research Institute

GLOBAL BCMA TARGETED THERAPIES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Bcma Targeted Therapies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Bcma Targeted Therapies Market Snippet by Type
    • 2.1.2. Bcma Targeted Therapies Market Snippet by Cancer
    • 2.1.3. Bcma Targeted Therapies Market Snippet by End-User
    • 2.1.4. Bcma Targeted Therapies Market Snippet by Country
    • 2.1.5. Bcma Targeted Therapies Market Snippet by Region
  • 2.2. Competitive Insights

3. Bcma Targeted Therapies Key Market Trends

  • 3.1. Bcma Targeted Therapies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Bcma Targeted Therapies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Bcma Targeted Therapies Market Opportunities
  • 3.4. Bcma Targeted Therapies Market Future Trends

4. Bcma Targeted Therapies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Bcma Targeted Therapies Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Bcma Targeted Therapies Market Landscape

  • 6.1. Bcma Targeted Therapies Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Bcma Targeted Therapies Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 7.1.2. Bispecific Antibodies
    • 7.1.3. Antibody Drug Conjugates
    • 7.1.4. Chimeric Antigen Receptor T-Cells

8. Bcma Targeted Therapies Market - By Cancer

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Cancer, 2023 & 2032 (%)
    • 8.1.2. Liver Cancer
    • 8.1.3. Respiratory Cancer
    • 8.1.4. Brain Cancer
    • 8.1.5. Others

9. Bcma Targeted Therapies Market - By End-User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Cancer Research Institute

10. Bcma Targeted Therapies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Bcma Targeted Therapies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Bcma Targeted Therapies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Bcma Targeted Therapies Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Bcma Targeted Therapies Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Bcma Targeted Therapies Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Cancer, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Bcma Targeted Therapies Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Transposagen Biopharmaceuticals
    • 11.2.2. Sutro Biopharma
    • 11.2.3. Malin Corporation
    • 11.2.4. Eureka Therapeutics
    • 11.2.5. firstVentury Equity
    • 11.2.6. Five Prime Therapeutics
    • 11.2.7. Credit Suisse Securities
    • 11.2.8. Dana-Farber Cancer Institute
    • 11.2.9. Deerfield Partners
    • 11.2.10. Onyx Pharmaceuticals
    • 11.2.11. Juno Therapeutics

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us